<DOC>
	<DOCNO>NCT00064233</DOCNO>
	<brief_summary>RATIONALE : BMS-354825 may stop growth cancer cell stop enzymes necessary cancer cell growth . PURPOSE : This phase I trial study side effect best dose BMS-354825 treating patient chronic phase chronic myelogenous leukemia resistant imatinib mesylate .</brief_summary>
	<brief_title>BMS-354825 Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant Imatinib Mesylate</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , maximum administer dose , dose-limiting toxicity , recommend phase II dose BMS-354825 patient chronic phase chronic myelogenous leukemia hematologic resistance imatinib mesylate . - Determine safety tolerability drug patient . - Determine plasma pharmacokinetics drug patient . - Determine , preliminarily , efficacy drug , term hematologic , cytogenetic , molecular response patient . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive oral BMS-354825 daily day 1-5 . Courses repeat every 7 day least 3 month absence disease progression unacceptable toxicity . Patients may receive treatment absence disease progression . Cohorts 3-6 patient receive escalate dos BMS-354825 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 20 additional patient receive treatment phase I MTD BMS-354825 . Patients follow least 30 day . PROJECTED ACCRUAL : Approximately 50 patient ( 30 phase I 20 phase II ) accrue study within 12-18 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis Philadelphia chromosome positive , chronic phase chronic myelogenous leukemia ( CML ) meeting follow criteria* : Less 15 % blast peripheral blood bone marrow Less 20 % basophils peripheral blood Less 30 % blast promyelocytes peripheral blood bone marrow Platelet count least 100,000/mm^3 NOTE : *Patients previously meet criterion accelerate phase blast phase CML , respond treatment , currently meet criterion chronic phase CML eligible Primary acquire hematologic resistance imatinib mesylate OR intolerance imatinib mesylate define follow : Primary hematologic resistance define failure reach complete hematologic response ( CHR ) dose 400 mg/day continue least 3 month Patients hematological progression ( i.e. , WBC least 10,000/mm^3 rise consistently least 2 consecutive measurement obtain least 14 day apart ) receive imatinib mesylate 400 mg/day eligible receive less 3 month therapy Acquired hematologic resistance define achieve CHR , subsequently develop rise WBC least 10,000/mm^3 WBC must least 10,000/mm^3 rise least 2 measurement obtain least 14 day apart least 1 measurement great 15,000/mm^3 Intolerance define discontinue imatinib mesylate due nonhematologic toxicity grade CD4^+ Tcell count least 350/mm^3 18 ECOG 01 Life expectancy , At least 6 month . Hepatic Bilirubin great 1.5 mg/dL ALT AST great 2.0 time upper limit normal ( ULN ) Renal Creatinine great 1.5 time ULN Potassium normal* Magnesium normal* Serum calcium ionized calcium least low limit normal NOTE : *Patients low level may replete eligible Negative pregnancy test Fertile patient must use effective contraception 1 month , , 1 month study participation More 14 day since prior interferon More 14 day since prior cytarabine More 3 day since prior hydroxyurea More 28 day since prior investigational antineoplastic agent More 7 day since prior imatinib mesylate At least 5 day 5 halflives since prior medication inhibit platelet function , include follow : Aspirin Dipyridamole Epoprostenol Eptifibatide Clopidogrel Cilostazol Abciximab Ticlopidine At least 5 day 5 halflives since prior anticoagulant warfarin heparin/low molecular weight heparin ( e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ) At least 5 day 5 halflives since prior drug accept risk cause torsades de pointes , include follow : Class IA antiarrhythmic agent ( e.g. , quinidine , procainamide , disopyramide ) Class III antiarrhythmic agent ( e.g. , amiodarone , sotalol , ibutilide , dofetilide ) Macrolide antibiotic ( e.g. , erythromycin clarithromycin ) Antipsychotics ( e.g. , chlorpromazine , haloperidol , thioridazine , pimozide ) Tricyclic antidepressant Cisapride Bepridil Inapsine Methadone Arsenic Concurrent anagrelide thrombocytosis due CML allow extramedullary involvement ( liver spleen ) significant bleed disorder unrelated CML acquire bleed disorder within past year ( e.g. , acquire antifactor VIII antibody ) congenital bleed disorder ( e.g. , von Willebrand disease ) uncontrolled significant cardiovascular disease uncontrolled angina within past 6 month congestive heart failure within past 6 month myocardial infarction within past 12 month history clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsades de pointes ) history second third degree heart block ( may eligible patient pacemaker ) diagnose suspected congenital long QT syndrome prolong QTc interval preentry EKG ( i.e. , great 450 msec ) heart rate le 50/minute preentry EKG uncontrolled hypertension vasculitis pregnant nursing gastrointestinal tract bleed within past 6 month connective tissue disorder serious uncontrolled medical disorder active infection would impair ability receive study therapy dementia alter mental status would preclude give informed consent evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , EKG , clinical laboratory determination unrelated CML prisoner patient compulsorily detain ( e.g. , involuntary incarceration treatment either psychiatric physical [ e.g. , infectious disease ] illness ) concurrent drug accept risk cause torsades de pointes concurrent treatment CML concurrent dolasetron droperidol concurrent anticoagulant concurrent medication inhibit platelet function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>